Does UnitedHealthcare Cover Weight Loss Treatment in New Hampshire? A 2026 Guide

Last updated: July 18, 2026

If you are a New Hampshire resident with a UnitedHealthcare (UHC) commercial plan and you are exploring weight loss medications, understanding what your insurance may cover. And what requirements apply. Can help you plan ahead and avoid unexpected costs. This guide covers the OptumRx formulary for common weight loss drugs, New Hampshire’s Electronic Prescribing of Controlled Substances (EPCS) rules under RSA 318-B:21-a, prior authorization requirements, and the regulatory framework that governs weight loss benefits on commercial plans in New Hampshire.

See if you may qualify for online weight loss treatment through Klarity Health. Our network of 2,000+ licensed providers can help you explore medication options and insurance coverage. Check your options with Klarity →

Key Facts for NH UHC Members (2026):

• PBM: OptumRx (manages UHC commercial formularies)
• GLP-1 medications (Wegovy, Zepbound, Saxenda): Typically Tier 3. 4, prior authorization required. BMI criteria apply.
• NH EPCS law (RSA 318-B:21-a): Covers Schedule II. IV controlled substances. Phentermine and Qsymia (Schedule IV) require electronic prescribing in New Hampshire. Unlike states where only Schedule II is covered.
• Medicare GLP-1 Bridge ($50/month): Applies to Medicare Advantage plans only. NOT applicable to commercial UHC plans.
• NH parity law (RSA 417-E:1): Covers mental health and substance use disorder. Does not govern weight loss medication coverage.
• Benefit scope: Weight loss drug coverage on commercial plans is governed by ACA Essential Health Benefits and ERISA, not NH parity statutes.
• Coverage varies by plan. Always verify benefits before beginning treatment.

Understanding UnitedHealthcare Weight Loss Coverage in New Hampshire

UnitedHealthcare is one of the largest commercial insurers in New Hampshire, offering plans on and off the Granite State’s ACA marketplace. Prescription benefits on UHC commercial plans are managed by OptumRx, UHC’s pharmacy benefit manager. Whether a specific weight loss medication may be covered. And at what cost. Depends on your individual plan’s formulary, tier placement, and any applicable prior authorization requirements.

It is important to distinguish between UHC commercial plans and UHC Medicare Advantage plans. Commercial coverage is governed by the Affordable Care Act, ERISA (for employer-sponsored plans), and your specific Summary of Benefits and Coverage. Medicare Advantage plans operate under entirely separate federal rules administered by CMS. This guide focuses on commercial UHC plans in New Hampshire.

OptumRx Formulary: Weight Loss Medications (2026)

The table below reflects typical OptumRx formulary placement for common weight loss medications on UHC commercial plans. Actual coverage depends on your specific plan. Always confirm with OptumRx or your plan’s member portal before beginning treatment.

Note: Formulary tiers and coverage criteria vary by plan year and individual plan design. Verify your specific benefits through the OptumRx member portal or by calling the number on your UHC member ID card.

New Hampshire EPCS Law: What Weight Loss Patients Need to Know

New Hampshire’s Electronic Prescribing of Controlled Substances law. Codified at RSA 318-B:21-a. Is notably broader than the EPCS rules in many other states. While some states require EPCS only for Schedule II controlled substances, New Hampshire’s statute covers Schedule II, III, and IV controlled substances, making it one of the more comprehensive EPCS mandates in the country.

For weight loss patients in New Hampshire, this has a direct practical impact:

• Phentermine (a Schedule IV controlled substance) must be prescribed electronically in New Hampshire under RSA 318-B:21-a. Providers practicing in New Hampshire must use a certified EPCS-enabled electronic health record system to prescribe phentermine.
• Qsymia (phentermine/topiramate extended-release, also Schedule IV) likewise requires electronic prescribing under RSA 318-B:21-a. Qsymia also carries a REMS program with additional prescriber and pharmacy certification requirements.
• GLP-1 medications (Wegovy, Zepbound, Saxenda, Ozempic used off-label for weight loss, Victoza) are not controlled substances and therefore are entirely outside the scope of EPCS requirements. No electronic prescribing mandate applies to these drugs.
• Contrave and orlistat are similarly non-scheduled and are not subject to NH EPCS requirements.

This is an important distinction from states like Hawaii, where the EPCS statute (HRS § 329-38.5) applies only to Schedule II controlled substances. Meaning phentermine and Qsymia (Schedule IV) do not trigger Hawaii’s EPCS requirements. In New Hampshire, the broader Schedule II. IV coverage of RSA 318-B:21-a means those same medications do require electronic prescribing.

Klarity Health’s providers are equipped to prescribe electronically in compliance with applicable state laws, including New Hampshire’s EPCS requirements.

Prior Authorization for Weight Loss Medications Under UHC/OptumRx

Most GLP-1 and GIP/GLP-1 weight loss medications on the OptumRx formulary require prior authorization on UHC commercial plans. PA criteria for Wegovy and Zepbound typically include:

• BMI of 30 or above, or BMI of 27 or above with at least one weight-related comorbidity (such as type 2 diabetes, hypertension, hyperlipidemia, or obstructive sleep apnea)
• Documentation of a supervised weight management program or lifestyle intervention attempt
• Confirmation the medication is being used for chronic weight management, not solely for glycemic control
• In some plans, step therapy. Requiring a trial of a lower-tier agent before approval of a specialty-tier GLP-1

For phentermine and Qsymia, PA requirements are typically less intensive, though quantity limits and duration-of-therapy restrictions often apply. Qsymia additionally requires enrollment in the REMS program (Risk Evaluation and Mitigation Strategy) through the prescriber and dispensing pharmacy.

To initiate a PA for a weight loss medication through UHC/OptumRx:

1. Your provider submits a PA request through Availity or the OptumRx provider portal (rxprotect.optum.com)
2. Standard PA decisions are typically issued within 15 calendar days for commercial plans (or 72 hours for urgent requests)
3. If denied, you may request an internal appeal, then an external independent review, and ultimately an external appeal through the NH Insurance Department

Does New Hampshire Parity Law (RSA 417-E:1) Require Weight Loss Coverage?

New Hampshire’s mental health and substance use disorder parity law. RSA 417-E:1 et seq.. Requires that commercial health plans cover mental health and substance use disorder benefits at parity with medical and surgical benefits. This is an important consumer protection for conditions like depression, anxiety, and ADHD.

However, RSA 417-E:1 applies specifically to mental health and substance use disorder benefits. It does not mandate coverage of weight loss medications or obesity treatment. Weight loss drug coverage on commercial plans is governed instead by:

• ACA Essential Health Benefits (EHB): The ACA’s EHB framework does not explicitly mandate weight loss medication coverage, so coverage depends on individual plan design and whether the employer or insurer has opted to include these benefits.
• ERISA: Most large employer-sponsored UHC plans are governed by ERISA (Employee Retirement Income Security Act), which generally preempts state insurance mandates. Meaning even if New Hampshire were to pass a weight loss coverage mandate, it may not apply to self-funded employer plans.
• Plan-specific benefit design: Some UHC employer plans include weight loss medications as a covered benefit by plan design, while others exclude them. Your Summary of Benefits and Coverage (SBC) will specify whether weight loss medications are covered on your plan.

If you are unsure whether your UHC plan covers weight loss medications, the fastest way to verify is to call the member services number on your insurance card and ask specifically about your prescription benefit for anti-obesity medications.

A Note on Medicare GLP-1 Bridge

You may have read about the CMS Medicare GLP-1 Bridge program, which as of July 1, 2026 allows eligible Medicare Advantage Prescription Drug (MAPD) plan members to access Wegovy, Zepbound, or Foundayo (oral tirzepatide) at approximately $50 per month through CMS-administered pricing. This program applies exclusively to Medicare Advantage plans and is not available on commercial UHC plans. If you are a UHC commercial plan member (not a Medicare Advantage member), this CMS bridge program does not apply to your coverage.

How to Check Your UHC Coverage for Weight Loss Medications

1. Log in to myuhc.com or the UHC mobile app. Use the formulary search tool under “Pharmacy Benefits” to look up your specific medication by name.
2. Call OptumRx at 1-800-788-4863 to speak with a pharmacy benefits specialist about your plan’s coverage and PA requirements.
3. Call UHC Member Services at the number on your insurance card (or 1-866-892-5890 for general inquiries) to confirm your weight loss benefit design and whether medications are included.
4. Ask your provider to run a benefit check before prescribing. Many EHR systems include real-time coverage verification tools.

Weight Loss Treatment at Klarity Health

Klarity Health connects New Hampshire residents with licensed medical providers who can evaluate your eligibility for weight loss medications. Including GLP-1 agonists like Wegovy and Zepbound, as well as other evidence-based options. With a network of 2,000+ providers and telehealth appointments available in New Hampshire, Klarity can help you explore options quickly and conveniently.

Klarity’s providers can:

• Assess your BMI and medical history to determine whether you may be a candidate for weight loss medications
• Submit prior authorization requests to OptumRx on your behalf
• Prescribe electronically in compliance with New Hampshire’s EPCS requirements under RSA 318-B:21-a
• Coordinate with your pharmacy and insurer throughout the PA process

Ready to explore your options? See if you may qualify for weight loss treatment through Klarity Health. Get started with Klarity →

Frequently Asked Questions

Does UnitedHealthcare cover Wegovy or Zepbound in New Hampshire?

Coverage for Wegovy and Zepbound depends on your specific UHC plan. Many commercial UHC plans manage these medications through OptumRx at Tier 3. 4 with prior authorization required. Some employer-sponsored plans exclude weight loss medications entirely. Check your Summary of Benefits and Coverage or call OptumRx at 1-800-788-4863 to confirm your specific coverage.

Does phentermine require a special prescription in New Hampshire?

Yes. Because phentermine is a Schedule IV controlled substance, New Hampshire’s EPCS law (RSA 318-B:21-a) requires that it be prescribed electronically. Your provider must use a certified EPCS-enabled system. Klarity Health’s providers are equipped to prescribe controlled substances electronically in compliance with New Hampshire law.

Is the Medicare $50/month GLP-1 program available on my UHC commercial plan?

No. The CMS Medicare GLP-1 Bridge program ($50/month for Wegovy, Zepbound, or Foundayo) applies only to Medicare Advantage Prescription Drug plans. It is not available on commercial UHC plans. If you are a Medicare Advantage member, contact your specific MA plan for information on this benefit.

Does New Hampshire’s parity law require my UHC plan to cover weight loss drugs?

No. New Hampshire’s parity law (RSA 417-E:1) applies to mental health and substance use disorder benefits only. It does not govern weight loss medication coverage. Whether your plan covers weight loss medications depends on your plan’s benefit design and applicable ACA Essential Health Benefit requirements.

What if my prior authorization for a weight loss medication is denied?

If OptumRx denies a PA request, you have the right to appeal. The appeal process for commercial UHC plans typically includes: (1) internal reconsideration by UHC, (2) external independent review, and (3) further appeals through the New Hampshire Insurance Department. Your provider can submit supporting documentation and clinical evidence to strengthen your appeal. Contact the NH Insurance Department at 1-800-852-3416 for guidance on your appeal rights.

Does Ozempic cover weight loss under my UHC plan?

Ozempic (semaglutide 0.5. 2 mg) is FDA-approved for type 2 diabetes management, not for chronic weight management. Wegovy (semaglutide 2.4 mg) is the same molecule at a higher dose, FDA-approved for weight loss. Many commercial plans cover Ozempic for diabetes but not for off-label weight loss use. If weight management is your goal, your provider should prescribe the FDA-approved weight loss indication (Wegovy) rather than Ozempic.

Key Contacts

• UHC Member Services: 1-866-892-5890 (or the number on your member ID card)
• OptumRx: 1-800-788-4863
• NH Insurance Department: 1-800-852-3416
• Klarity Health (weight loss): helloklarity.com/service/weight-loss

Disclaimer: This article is for informational purposes only and does not constitute medical or legal advice. Insurance coverage for weight loss medications varies significantly by plan, employer, and individual circumstances. Coverage information reflects general OptumRx formulary patterns as of mid-2026 and may not reflect your specific plan. Always verify your benefits directly with UHC/OptumRx before beginning treatment. The NH EPCS information reflects RSA 318-B:21-a as in effect as of the date of this publication. Consult with your provider or pharmacist for the most current requirements.